Pharmafile Logo

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

April 13, 2026 |  

Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.

- PMLiVE

Medical publications are navigating a period of rapid change. From artificial intelligence and automation to transparency, governance, patient partnership, and evolving impact measurement, the pressure to deliver faster must now coexist with the responsibility to maintain scientific rigour and trust. 

Inizio Medical’s ISMPP EU 2026 Insights Report captures the most consequential discussions from the meeting and outlines the emerging strategic implications for publication teams. 

More than just a meeting summary, this is Inizio Medical’s informed perspective on how publication practices are evolving and how teams can adapt to ensure they remain efficient, ethical, and impactful in 2026 and beyond. 

Download the full report here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Nutraceuticals: Rich in Potential

Published in eyeforpharma October 2016 by Marc Yates

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in...

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

Evolution from man to machine

Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...

Time for a new language for asthma?

Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines....

Evaluating the impact of your medical congress presence…more cost effectively

Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year....